A Phase 1, Multiple-Dose, Open-Label, Randomized, Crossover Study in Healthy Subjects to Assess the Effect of Pioglitazone (PGZ) on the Pharmacokinetics (PK) of Cenicriviroc Mesylate (CVC) and the Effect of CVC on the PK of PGZ
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2015
At a glance
- Drugs Cenicriviroc (Primary) ; Pioglitazone
- Indications Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Tobira Therapeutics
- 01 Oct 2015 Results will be presented at the AASLD Annual Meeting, as per Tobira media release.
- 11 Aug 2015 Positive results from this study will be presented at a medical meeting later this year, as per Tobira media release.
- 11 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.